Lipocine Showcases Innovative Oral Delivery Solutions at H.C. Wainwright Investment Conference

Lipocine's Innovative Approach to Oral Delivery in Biopharma

Lipocine Inc., a biopharmaceutical company focused on innovative oral delivery systems, is poised to showcase its advancements at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company plans to provide a presentation beginning at 7:00 a.m. EDT on September 5, 2025, detailing its latest developments and future directions. Lipocine's commitment to addressing significant unmet medical needs through its novel oral delivery products positions it as a leader in the biopharmaceutical industry. By prioritizing patient experience and treatment efficacy, Lipocine aims to reshape how various conditions are treated, targeting large markets that demand effective solutions.

Among Lipocine's most promising clinical candidates is LPCN 1154, an oral formulation of brexanolone designed to address postpartum depression, a condition that affects many women worldwide. This innovative approach not only offers a more acceptable method of administration but also enhances patient compliance, a critical factor in mental health treatment. Additionally, LPCN 2101 targets epilepsy, LPCN 2203 is aimed at treating essential tremor, and LPCN 2401 serves as an anabolic androgen receptor agonist for obesity management. Each candidate reflects Lipocine's strategy of developing differentiated oral therapies that can potentially improve quality of life for patients suffering from these conditions.

Furthermore, Lipocine is actively seeking partnerships to expand its portfolio, particularly for candidates like LPCN 1107, which focuses on preventing preterm birth, and LPCN 1144, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). The company has already achieved a significant milestone with TLANDO, an oral testosterone prodrug that has received FDA approval for treating hypogonadism in adult males. This approval underscores Lipocine’s innovative capabilities and reinforces its mission to deliver groundbreaking oral therapies that fulfill critical healthcare needs.

In addition to its clinical advancements, Lipocine encourages interested investors and stakeholders to engage with its management during the upcoming conference. By facilitating one-on-one meetings through H.C. Wainwright, the company aims to foster deeper connections and discussions about its innovative pipeline. For more information on Lipocine and its ongoing projects, the company invites interested parties to visit its website at www.lipocine.com.